Thursday, November 6, 2025

Thomas Meier to take over as CEO of Medios AG in February 2026, leading the company into its next phase of growth

The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board effective February 1, 2026, and designated him as the company’s new Chief Executive Officer (CEO). He succeeds Matthias Gaertner, who will remain in office until December 31, 2025.

Thomas Meier brings extensive international leadership experience in the pharmaceutical industry. Since 2020, he has served as CEO of the Swiss Bachem Holding AG, a publicly listed CDMO (Contract Development and Manufacturing Organization). Prior to that, he held the position of Chief Operations Officer at Bachem and led manufacturing at Peninsula Laboratories in San Carlos, California (USA), from 2001 to 2004.

With Thomas Meier, Medios gains an experienced leader with a strong record of capital-efficient, profitable growth. He is expected to play a key role in driving the further expansion of the Medios Group.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, stated:“With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial mindset, expertise, and leadership will significantly contribute to achieving our ambitious goals and sustainably enhancing value for our shareholders, partners, and customers.”

At the same time, the Supervisory Board expressed its sincere gratitude to Matthias Gaertner for his outstanding work and great commitment over the past ten years, during which he played a decisive role in shaping the growth and success of Medios AG.

Thomas Meier commented: “I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios’ position in the European Specialty Pharma market.”